Current partner codePEPTIDESDE
NCT03573908·Phase 3·INTERVENTIONAL

A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Status

Completed

Phase

Phase 3

Enrollment

614

Locations

79

Results

Posted

Publications

2

Study summary

What the protocol is testing.

To evaluate the efficacy on abdominal symptoms (abdominal bloating, abdominal discomfort, and abdominal pain) and safety of linaclotide 290 μg administered orally to patients with IBS-C.

Full detailed description

This study consists of a 12-week Treatment Period followed by 4-week Randomized Withdrawal (RW) Period.

Interventions

Treatment arms and agents.

DRUG

Linaclotide

Oral capsule

DRUG

Placebo

Matching placebo oral capsule

Timeline

From registration to results.

  1. First posted

    Jun 29, 2018

  2. Study start

    Jun 20, 2018

  3. Primary completion

    Mar 13, 2019

  4. Study completion

    Apr 10, 2019

  5. Results posted

    Nov 16, 2020

  6. Registry updated

    Dec 1, 2020

Outcomes

What the study measures.

Primary outcomes

Overall Change From Baseline in Abdominal Score (Abdominal Bloating, Abdominal Discomfort, and Abdominal Pain) Throughout the Treatment Period

Time frame · Baseline (14 days before randomization up to the time of randomization), Treatment Period (Weeks 1-12)

A participant's daily abdominal score was calculated as the average of daily e-diary abdominal pain, abdominal bloating and abdominal discomfort scores, each based on an 11-point scale of 0 (none) and 10 (worst possible). Baseline abdominal score was derived from the eDiary data collected daily in the Pretreatment Period, specifically the period of time from 14 days before randomization up to the time of randomization. The participant's abdominal score was averaged on a weekly basis, and each weekly change from baseline was calculated for the treatment period and used as the dependent variable in the mixed model with repeated measures (MMRM) model. MMRM results are based on a model with treatment, analysis week, region and treatment-by-week interaction as fixed effects and baseline as a covariate. An unstructured covariance structure was used to model intra-subject correlation with subjects as a random effect.

Secondary outcomes

Cumulative Distribution of Change From Baseline in 12-Week Abdominal Score

Time frame · Baseline (14 days before randomization up to the time of randomization), Treatment Period (Weeks 1-12)

A participant's daily abdominal score was calculated as the average of daily e-diary abdominal pain, abdominal bloating and abdominal discomfort scores, each based on an 11-point scale of 0 (none) and 10 (worst possible). Baseline abdominal score was derived from the eDiary data collected daily in the Pretreatment Period, specifically the period of time from 14 days before randomization up to the time of randomization. The 12-week abdominal score was the average of the non-missing abdominal scores reported over the course of the treatment period. Change from baseline (BL) was calculated as the 12-week score minus the baseline score. The table presents the percentage of participants whose 12-week change from baseline was less than or equal to the threshold value of the score change (cumulative distribution of change).

Percentage of 6/12 Week Abdominal Score Responders (Responder Rate)

Time frame · Baseline (14 days before randomization up to the time of randomization), Treatment Period (Weeks 1-12)

A 6/12 week abdominal score responder is a participant who meets the weekly abdominal score responder criteria for at least 6 out of the 12 weeks of the Treatment Period. For each week in the Treatment Period, a weekly abdominal score responder is a participant who has an improvement from baseline of at least 2 points (ie, a -2 point change from baseline) in the respective weekly abdominal score. If a participant did not have at least 4 completed eDiary entries for a particular Treatment Period week, the participant was not considered a responder for that week. A participant's daily abdominal score was calculated as the average of daily e-diary abdominal pain, abdominal bloating and abdominal discomfort scores, each based on an 11-point scale of 0 (none) and 10 (worst possible). The participant's abdominal score was averaged on a weekly basis, and each weekly change from baseline was calculated for the treatment period.

Overall Change From Baseline in Abdominal Score (Abdominal Bloating, Abdominal Discomfort, and Abdominal Pain) Over Time in the Treatment Period

Time frame · Baseline (14 days before randomization up to the time of randomization), Weeks 1-12

A participant's daily abdominal score was calculated as the average of daily e-diary abdominal pain, abdominal bloating and abdominal discomfort scores, each based on an 11-point scale of 0 (none) and 10 (worst possible). Baseline abdominal score was derived from the eDiary data collected daily in the Pretreatment Period, specifically the period of time from 14 days before randomization up to the time of randomization. The participant's abdominal score was averaged on a weekly basis, and each weekly change from baseline was calculated for the treatment period and used as the dependent variable in the mixed model with repeated measures (MMRM) model. MMRM results are based on a model with treatment, analysis week, region and treatment-by-week interaction as fixed effects and baseline as a covariate. An unstructured covariance structure was used to model intra-subject correlation with subjects as a random effect.

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
Not reported
Sex
ALL
Healthy volunteers
No

Inclusion Criteria: * Patient has no clinically significant findings on a physical examination and clinical laboratory tests * Female patients of childbearing potential must agree to use one of the following methods of birth control: 1. Hormonal contraception 2. Double-barrier birth control 3. Maintenance of a monogamous relationship with a male partner who has been surgically sterilized by vasectomy * Patient meets protocol criteria for diagnosis of IBS-C * Patient demonstrates continued IBS-C symptoms through Pretreatment Period * Patient maintains a minimum level of compliance with daily diary Exclusion Criteria: * Patient has history of loose or watery stools * Patient has symptoms of or been diagnosed with a medical condition that may contribute to abdominal pain * Patient has a structural abnormality of the gastrointestinal (GI) tract or a disease or condition that can affect GI motility * Patient has any protocol-excluded or clinically significant medical or surgical history that could confound the study assessments

Study locations

79 registered sites.

United States. Showing up to 24 locations stored in the fast local snapshot.

Clinical Research Associates

Huntsville, Alabama, United States

Elite Clinical Studies

Phoenix, Arizona, United States

Adobe Clinical Research, LLC

Tucson, Arizona, United States

Arkansas Gastroenterology

North Little Rock, Arkansas, United States

GW Research, Inc.

Chula Vista, California, United States

Kindred Medical Institute for Clinical Trials, LLC

Corona, California, United States

Diagnamics, Inc.

Encinitas, California, United States

MD Studies, Inc.

Fountain Valley, California, United States

Paragon Rx Clinical, Inc. - Garden Grove

Garden Grove, California, United States

Grossmont Center For Clinical Research

La Mesa, California, United States

Facey Medical Foundation

Mission Hills, California, United States

Providence Clinical Research

North Hollywood, California, United States

Precision Research Institute

San Diego, California, United States

Paragon Rx Clinical, Inc.- Santa Ana

Santa Ana, California, United States

Millennium Clinical Trials

Thousand Oaks, California, United States

St. Joseph Heritage Healthcare

Yorba Linda, California, United States

Connecticut Clinical Research Institute

Bristol, Connecticut, United States

Chase Medical Research, LLC

Waterbury, Connecticut, United States

Clinical Research of South Florida

Coral Gables, Florida, United States

Avail Clinical Research, LLC

DeLand, Florida, United States

Palmetto Research, LLC

Hialeah, Florida, United States

Nature Coast Clinical Research, LLC

Inverness, Florida, United States

The Chappel Group Research

Kissimmee, Florida, United States

Jesscan Medical Research

Miami, Florida, United States

Related trials

More studies on Linaclotide.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.